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SUMMARY
Painless dental treatment is of major interest in 
pediatric dentistry. Local anesthesia contains 
epinephrine, which prolongs soft tissue anesthe-
sia. This, however, is often a source of discomfort 
for children and is responsible for certain side 
 effects (e.g., self-inflicted soft tissue lesions).  
The aim of this study was to investigate whether 
an epinephrine-reduced articaine solution could 
 reduce the duration of soft tissue anesthesia and 
thereby reduce the risk of self-inflicted soft 
 tissue lesions, while still providing an adequate 
anesthesia. 
In a non-interventional clinical study, routine 
dental treatment was performed on children and 
adolescents. An articaine 4% solution with an 
epinephrine-reduced solution (Ubistesin™ mite, 
1:400,000) and a conventional epinephrine solu-
tion (Ubistesin™ forte, 1:100,000) were compared 
in terms of duration of soft tissue anesthesia.
One hundred and fifty-eight patients (mite: 75, 
forte: 83) were treated (80% with infiltration an-
esthesia). In both groups, the average volume of 
the injection was comparable (mite: 1.2 ml, forte: 
1.1 ml). One patient from each group showed 
 unwanted side effects. In both groups, the local 
anesthesia was complete or sufficient (96%) to 
perform the planned treatment. The average 
treatment time was 24 minutes in the mite group 
and 28 minutes in the forte group. The difference 
in mean duration of soft tissue anesthesia was 
statistically significant (p = 0.001, mite: 2.1 h, 
forte: 2.8 h).
Thanks to its high efficacy, tolerance, and reduced 
soft tissue anesthesia, the articaine 4% solution 
with the reduced epinephrine concentration 
(1:400,000) was considered a safe and suitable 
drug for routine treatments in pediatric dentistry.
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Introduction
Adequate, successful pain and fear management is critically 
important in modern pediatric dentistry. Thus, it is very im-
portant today that a successful elimination of pain include 
the control of fear. It is now known that until they reach 
school age, children cannot differentiate between the expe-
rience of pain and the feeling of discomfort/anxiety (Raadal 
et al. 2009). Negative  experiences and pain during dental 
treatment can become  anchored in a child’s memory. This 
initiates pain learning processes that manifest in the neuro-
matrix (Daubländer 2005). Hence, in the interest not only of 
the patient but also the dentist, this phenomenon should be 
avoided whenever possible.
Therefore, adequate elimination of pain during dental 
treatment of children and adolescents is a conditio sine qua 
non. In pediatric dentistry, local anesthesia is still the meth-
od of choice for pain elimination and can thus be considered 
the gold standard (Daubländer 2006). Hence, choosing the 
right local anesthetic is of special significance. Because of its 
sufficient anesthetic effect in combination with a low level of 
toxicity, a 4% solution of articaine – which is part of the acid 
amide complex with a thiophene ring at the aromatic end – is 
used in routine dental procedures (Bader & Lambrecht 2001). 
Side effects can be avoided by using a weight-based dosage 
(Ahmed & Martinez 2009). In order to prolong the duration of 
local anesthetics as well as avoid serious systemic side effects 
due to a lower level of plasma, a vasoconstrictor (Lipp et al. 
1993, Yagiela 1995), usually epinephrine, is added to the com-
pound (Paxton & Thome 2010). However, a child’s vegetative 
nervous system can react very sensitively to systemic side 
 effects caused by epinephrine  (Istaphanous & Loepke 2009). 
Furthermore, epinephrine prolongs the effects of the anes-
thetic, thus increasing the risk of self-inflicted soft tissue 
 lesions, for example, biting of the tongue or lip (Ram & Amir 
2006).
The Ubistesin™ mite injection solution is approved by the 
manufacturer (3M ESPE, Seefeld, Germany) for dental therapy 
in children above the age of four and adolescents with certain 
approved indications. The drug consists of articaine hydrochlo-
ride (40 mg/ml) and epinephrine as hydrochloride (2.5 µg/ml in 
a corresponding dilution of 1:400,000). What makes Ubistes-
in™ mite different from the conventional compounds is its low 
level of epinephrine (Ubistesin™ forte: 1:100,000, Ubistesin™ 
1:200,000). Therefore, the effects on the circulatory system are 
expected to be less severe when administering the compound 
accordingly. Additionally, one can assume that a lower concen-
tration of the vasoconstrictor reduces the duration of the soft 
tissue anesthesia. To supplement previously published studies 
of other local anesthetics with higher concentrations of epi-
nephrine used in children, the purpose of this observational 
study was to specifically document the effects profile and com-
patibility when treating children and adolescents in terms of 
lower epinephrine concentrations and the duration of the soft 
tissue anesthesia.
The aim of this study was to examine and compare the clinical 
benefits of Ubistesin™ mite and Ubistesin™ forte injection 
solution on children and adolescents under routine conditions 
in a dental practice. The criteria for success were the effective-
ness, duration, tolerability, and safety of the chosen anesthetic. 
Simultaneously, the side effect profile on children and adoles-
cents and the areas of application in restorative dentistry were 
recorded.
Materials and Methods
Study design and selection of patients
To meet the ethical requirements of such a study, the patients 
or their parents were informed in writing about the purpose, 
content, and data security of the study. Participation in the 
study was voluntary, and patients had the right to revoke their 
participation at any time without stating reasons. The ethics 
votum of the Cantonal Ethics Commission was positive.
This was an observational study without intervention in the 
usual clinical treatment of the patients. The monocentric clini-
cal study examined 176 patients (87 mite, 89 forte) who were 
recruited in the third quarter of 2011 at a study center (Clinic  
for Orthodontics and Pediatric dentistry, University of Zurich) 
with several satellite clinics (school dental clinics of the City of 
Zurich).
All patients aged 4 to 17 (the main target group was ages 4 
to 12) and their parents/legal guardians were asked to partici-
pate in the study if infiltration, block or intra-ligament anes-
thesia was planned for a routine treatment, thus making the 
 selection of patients random. The allocation into the two groups 
was done by drawing lots, with the exception of a very few, 
more extensive surgical cases. Neither the patients nor their 
parents/guardians were told which group they were sorted 
into. The routine treatments to be included were those in the 
deciduous and permanent dentition that were not expected  
to take longer than 30 minutes: presumably easy extractions, 
treatment of lesions to the dentin caused by trauma, endodon-
tic procedures, inserting stainless steel crowns, and cavity and 
crown-stump preparations. Suitable consecutive patients who 
had given their consent were included in the study. Each pa-
tient was included in the observational study only once. There-
fore, if a patient took part in the study, it had to be noted in  
his or her medical history. Reasons for excluding patients were 
all the absolute contraindications mentioned in Ubistesin’s™ 
product information sheet. Other criteria for exclusion from the 
study were suspected drug addictions, chronic or spontaneous 
ingestion of painkillers or psychotherapeutic drugs at the time 
of dental treatment, and cardiovascular diseases as well as sub-
optimal general health with risk classifications of ASA 3 (Amer-
ican Society of Anesthesiology) and ASA 4. Further reasons for 
exclusion of patients were relative contraindication of the test 
substance, as well as mucogingival surgery (labial or lingual 
frenulum surgery), surgical exposure of impacted teeth, ex-
traction of the 12-year molar, a planned osteotomy, the treat-
ment of acute trauma-related lesions as well as surgical proce-
dures that called for postoperative analgesia over several hours 
and prolonged vasoconstriction for ischemia. 
The local anesthetics used were 4% articaine in 1.7-ml car-
tridges with an epinephrine concentration of either 1:100,000 
(Ubistesin™ forte) or 1:400,000 (Ubistesin™ mite).
Examination procedure
Before the study began, every patient and/or their parent/
guardian gave their written consent that they had been in-
formed about the study in detail and that all questions they 
might have had been answered to their satisfaction. After re-
viewing the patients’ medical history and determining their 
weight, the findings (tooth, area, indication) were documented 
on the patient datasheet in preparation for dental treatment. 
The decision whether or not to sedate the patient in addition to 
applying the local anesthesia was left up to the dentist. Here, 
type, drug, and concentration were documented. Depending 
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on the indication the appropriate technique of application was 
chosen (infiltration, block or intra-ligament anesthesia). The 
time of injection of the anesthetic, as well as the amount and 
injection technique were documented. If several areas were 
anesthetized, only one tooth or area of up to three neighboring 
teeth was observed and documented. In these cases, the quad-
rant that was treated first was included in the study. If a second 
injection was necessary, time, amount, and anesthetic used as 
well as the technique of application were noted. The length of 
the entire treatment was documented by the treating dentist. 
The treating dentist also evaluated the anesthesia using certain 
scores:
 –  Score 3: completely effective (treatment is completely 
 painless) 
 –  Score 2: sufficiently effective (slightly painful treatment,  
yet no additional injection necessary) 
 –  Score 1: insufficiently effective (painful treatment, and 
 depending on the intensity of the pain, second injection 
 necessary) 
 –  Score 0: no effect (second injection necessary)
 –  Evaluation not possible (treatment could begin only at least 
ten minutes after the first injection, uncertain whether effects 
had worn off) 
Until an evaluation was made, a latency period of 5 to 7 minutes 
was allowed to elapse. A premature termination of the planned 
treatment as well as its reasons had to be documented. The time 
point at which restored, complete, normal sensation was ascer-
tained – which marks the end of the soft tissue anesthesia – as 
well as possible unwanted events (systemic or local) were doc-
umented by contacting the patients/their parents via telephone 
on the day of the treatment or the following day. Unwanted 
 local events were, for example, hematomas and bite lesions 
(cheek, lip, tongue). In the examination report, every harmful 
incident that befell the patient after the drug was administered, 
regardless of whether or not it could be linked to the treatment, 
was defined as an unwanted event. However, in cases of un-
wanted drug effects, equal to side effects, a causal link between 
the unwanted event and the drug was assumed. The entire peri-
od of observation was 14 days.
Statistical evaluation
All parameters of this open, explorative observational study 
were evaluated using descriptive statistics.
To analyze the reduced duration of the soft tissue anesthesia 
in the two groups (Ubistesin™ mite and Ubistesin™ forte), the 
results were subjected to a parametric two-sample t-test.
The sample size was determined using a power sample-size 
test. Assuming a standard deviation of +/–60 minutes and an 
expected difference of 25 to 30 minutes, an accuracy of 75% 
with a mean difference of 25 minutes could be expected, but 
with a mean difference of 30 minutes, an accuracy of 88% could 
be expected with 80 patients. Based on these calculations and 
the acceptance of an accuracy of about 80%, the number of 
 patients per group was set at 80.
Results
Patients
Of the 176 patients (87 Ubistesin™ mite, 89 Ubistesin™ forte), 
12 patients from the mite group and 6 patients from the forte 
group could not be included in the evaluation due to inadequa-
cies in informed-consent forms or not meeting the inclusion 
criteria. In two cases, the treatment of a patient from the mite 
group had to be discontinued and in one case from the forte 
group. These patients were not included in the evaluation of  
the time needed for the treatment or the duration of the effects 
of the anesthesia; they were, however, included in the other 
descriptive evaluations. The set age requirement of 4 to 17 years 
was fulfilled in both groups and the distribution of gender  
was even (mite: 38 female, 37 male; age: x = 8.37 years, 4–15, 
SD = 2.42; forte: 39 female, 44 male; age: x = 7.99 years, 4–16, 
SD = 2.30). In the end, the data of a total of 158 patients (mite: 
75, forte: 83) were evaluated who had been treated at the six 
study centers within the third quarter of 2011. In both groups 
60% of the examinations were conducted in three study centers 
(Schulzahnklinik Nord, Schulzahnklinik Unterstrass, and 
Schulzahnklinik Aussersihl). The patients’ average weight was 
31.25 kg in the mite group (18–79, SD = 11.41) and 29.87 kg in the 
forte group (15.6–76.5, SD = 11.82). There were no known aller-
gic reactions to the local anesthetic or its components in any of 
the patients.
Indications for treatment/areas of application
In about 90% of the cases in both study groups, the following 
indications for treatment were listed. Mite: 49/75: preparation 
of cavities at the D3 level; 16/75: extractions of primary teeth 
(70% posterior teeth, 30% anterior teeth); 4/75: preparation of 
cavities at the D3/D4 level; other indications for treatment: 8%. 
Forte: 51/83: preparation of cavities at the D3 level; 16/83: ex-
tractions of primary teeth (60% posterior teeth, 40% anterior 
teeth); 8/83: preparation of cavities at the D3/D4 level; other 
indications for treatment: under 10%.
Anesthesia
In 80% of the cases, dental treatment was conducted without 
additional sedation. With almost 20% of the mite patients 
(13/75) and a good 10% (9/83) of the forte patients, inhalation 
sedation was implemented with nitrous oxide.
The most commonly used injection technique was infiltration 
anesthesia. This type of anesthesia was performed on about 
80% of the patients (mite group: 60/75; forte group: 66/83). 
Block anesthesia was used in 13% of the cases in the mite group 
(10/75), and with Ubistesin™ forte in about 11% of the cases 
(9/83). Furthermore, combinations of injection techniques 
were done, for instance the combination of infiltration and 
block anesthesia (mite 2/75; forte 7/83), and the combination  
of infiltration and intra-ligament anesthesia (mite 2/75; forte 
1/83). In both groups, the mean amount injected was about the 
same (mite: 1.2 ml, SD = 0.29; forte: 1.1 ml, SD = 0.30).
Side effects
In each group, one patient showed unwanted side effects. These 
were rated as non-serious: one patient from the mite group was 
diagnosed with nausea post-operatively (1/75), which, how-
ever, disappeared spontaneously. One patient from the forte 
group complained of a headache (1/83), which also sponta-
neously wore off. The dentist who had performed the treatment 
rated the causal link as non-assessable.
Efficacy and duration of soft tissue anesthesia
In both study groups, complete to sufficient effectiveness of  
the anesthesia was achieved in 96% of the cases (mite: 72/75; 
forte: 80/83) (Fig. 1). Three patients from each group judged the 
 effects of the anesthesia as insufficient. In the mite group, two 
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(2/75) second injections were applied, where subsequently one 
treatment could be conducted completely, but the other had to 
be prematurely discontinued due to persistent pain. The treat-
ment of one patient had to be terminated prematurely due to 
a lack of cooperation. In three cases, patients from the forte 
group also judged the effects of the anesthesia as being insuffi-
cient (3/83), and all three patients were given a second injec-
tion. In two cases, this led to a successful conclusion of the 
treatment. Due to poor cooperation, the treatment of one 
 patient had to be terminated prematurely.
The mean time required for the treatment was 24 minutes 
(SD = 10.2) for the Ubistesin™ mite group, and 28.4 minutes 
(SD = 12.7) for the Ubistesin™ forte group. In the mite group, the 
treatment time for cavity preparation at the D3 level with one 
to two adjoining teeth was an average of 27 minutes (SD = 9.4), 
the treatment time for the extraction of one to two adjoining 
deciduous teeth was a mean of 13 minutes (SD = 6.5). In the forte 
group, the treatment time for cavity preparation at the D3 level 
under the same circumstances was about 28 minutes (SD = 8.2), 
and an extraction of one to two adjoining deciduous teeth took 
about 23 minutes (SD = 19.5).
The datasets for the mean duration of the effects of the 
 anesthesia and thus the duration of the soft tissue anesthesia 
showed that the effects of Ubistesin™ mite lasted for 126.2 min-
utes (SD = 64.1), and those of the forte compound lasted for 
166.0 minutes (SD = 94.2). The differences are statistically sig-
nificant (p = 0.001) (Fig. 2).
Discussion
In pediatric dentistry, it is mandatory to recognize pain and 
treat it, as well as to take preventive measures against pain. Be-
ing a conventional tool of dentistry, local anesthetics are one of 
the most frequently administered drugs (Malamed 1990). Arti-
caine chloride with an added vasoconstrictor is quite popular 
for local pain elimination in the dental treatment of children 
and adolescents. The added epinephrine reduces the risk of 
 intoxication through delayed washout, which increases the 
available threshold quantity. Safe pulp and soft tissue anesthesia 
offers a wide range of indications for conservative-surgical 
treatment of children. Bite lesions due to prolonged soft tissue 
anesthesia, however, pose a relatively common problem that 
should not be underestimated. In their study, Adewumi et al. 
(2008) examined the side effects that occurred in connection 
with articaine, and reported an increased number of transient 
sensation disturbances. Forty percent of the patients com-
plained of numbness three hours after treatment, and after five 
hours, 11% still complained of numbness. Accordingly, 14%  
of the children incurred bite lesions, mainly of the lip. These 
unwanted accompanying events can be partially attributed to 
the vasoconstrictor (Meechan et al. 2001). To date, the safety 
and effect of a 4%  articaine and a 2% lidocaine solution with a 
1:100,000 and 1:200,000 addition of epinephrine have been ex-
amined in several studies (Dudkiewicz et al. 1987, Wright et al. 
1989, Wright et al. 1991). Boynes et al. (2013) published a paper 
in which the rate of complications after the injection of a vaso-
dilator (phentolamine) that shortens the duration of the soft 
tissue anesthesia was examined. The duration of numbness of 
cheeks, lips, and tongue could be reduced by almost half by a 
second injection into the anesthetized area at the end of the 
dental treatment. So far, this alpha-adrenergic antagonist is 
only approved in the USA and Germany. A recently published 
paper showed the clinical benefits of a 4% articaine solution 
with epinephrine at a concentration of 1:400,000 (Kämmerer et 
al. 2013). However, there is no data to date comparing the two 
drugs directly. Thus, the question at hand was whether or not 
the length of the paresthesia, which caused the bite lesions in 
children, could be verifiably reduced by using an epinephrine- 
reduced anesthetic (1:400,000) instead of the usual compound 
(1:100,000).
The age and gender distribution as well as the indications for 
treatment were similar in the mite and the forte group. In both 
groups, about two-thirds of the cases (mite: 49/75, forte: 51/83) 
were preparations of cavities at the D3 level. The second most 
common area of application was the extraction of deciduous 
teeth, with about 20% in both groups (mite: 16/75, forte: 16/83). 
Therefore, the differences that appeared in the evaluation were 
discarded as irrelevant. The data concerning the additional se-
dation through inhalation were, however, less similar. In the 
mite group, nitrous oxide was used almost twice as often as in 
the other group (mite: 13/75, forte 9/83).
*
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The injection technique, however, was the same in both 
groups again. For about 80% of the treatments, an infiltration 
technique was used. About every tenth anesthesia was per-
formed by blocking the inferior alveolar nerve (mite: 10/75, 
forte: 9/83). Almost the same amount of anesthetic was admin-
istered in both groups (mite: 1.2 ml, forte: 1.1 ml). The occur-
rence of unwanted side effects (1%) was also identical; in both 
groups, one patient showed a non-serious, spontaneously sub-
siding event. These results match those of a recently published 
Australian study that examined serious unwanted events due  
to local anesthesia and found that such events are very rare 
(Sambrook et al. 2011). In our study, no damage to the soft 
 tissue caused by biting was reported. 
A success rate of 97% of the initial injection in the mite group 
and 96% in the forte group, as well as successful completion of 
treatment of 97% in the mite group and 99% in the forte group 
prove a very high efficacy for both of the tested anesthetics. The 
success rate of the initial injection in the mite group was even 
higher than in a comparable study by Kämmerer et al. 2013. The 
higher success of the mite group may be explained by the fact 
that the treating dentist automatically used Ubistesin™ forte if 
more demanding surgical procedures were necessary. This cre-
ated a bias. Through a strictly randomized assignment of the 
patients, the resulting difference might change. The same 
thoughts apply to the following results: due to two particular 
cases that were more time consuming, the average time needed 
for treatment was slightly longer in the forte group than in the 
mite group (mite: 24.0 minutes, forte: 28.4 minutes). The treat-
ment of patients from the forte group tended to take slightly 
longer. If the data from those two cases were eliminated, the 
rest of the data stayed within a normal distribution. The mean 
was reduced to 27.4 minutes (SD = 10.3), and the time needed 
for the treatments was equally long. The time required for the 
preparation of a cavity was almost identical (mite: 27 minutes, 
forte: 28 minutes). However, this was not the case for the time 
required for extractions. While an extraction of one to two ad-
joining deciduous teeth took 13 minutes in the mite group, the 
average time needed for an extraction in the forte group was 
about ten minutes longer, thus being 23 minutes.
One of the most important results of this study was the cor-
relation between the concentration of epinephrine in the an-
esthetic and the duration of the soft tissue anesthesia. It was 
proven that the patients from the mite group experienced a 
 significantly shorter duration of soft tissue anesthesia than did 
the patients from the forte group (p = 0.001). Furthermore, the 
boxplot indicates that the outliers of the forte group are more 
extreme. This is a very important issue for pediatric dentistry 
which should not be underestimated, because a large number  
of postoperative complications comprise the self-inflicted le-
sions commonly seen in dental practices. These mostly involve 
the lips, but also the tongue and cheeks, due to the prolonged 
paresthesia. This observation could, however, not be confirmed 
definitively in clinical studies (Ram & Amir 2006); these authors 
reported the effects of the anesthetic to persist for 3.43 (SD = 0.7) 
hours. Kämmerer et al. (2013) reported a duration of 2.19 hours 
when using a 4% articaine solution with 1:400,000. Our results 
were 2.1 hours for the mite group and 2.8 hours for the forte 
group. Differentiation based on type of local anesthesia used 
was not possible on account of the small number of cases. 
Therefore, a total mean was determined with a comparable 
 distribution in both groups. Consequently, the use of an epi-
nephrine-reduced compound shortens the duration of soft 
 tissue anesthesia, a condition which is both unpleasant and 
dangerous for children. In contrast to other studies (Adewumi et 
al. 2008, Boynes et al. 2013), none of the patients in our study 
showed any unwanted local events, probably owing to the fact 
that the children were informed in such detail about these risks, 
and watched closely to prevent lesions of this kind.
In the present study, the clinical benefits of both anesthetics 
were examined and compared. The epinephrine-reduced com-
pound proved to be effective, sufficient in duration, and tolera-
ble. The 4% articaine solution with an added vasoconstrictor of 
1:400,000 is clearly advantageous for pediatric dentistry, where 
insuring adequate elimination of pain with as few side effects as 
possible is of vital importance.
In accordance with the study protocol, the mite compound 
with a pulp anesthesia time of about 30 minutes is recommend-
ed without restriction for the shorter routine treatments in pe-
diatric dentistry. Using this compound for indications that re-
quire a prolonged pre- and postoperative period of anesthesia or 
an ischemia should be evaluated critically. However, the use of 
the conventional compound with a higher level of epinephrine 
is still recommended for treatments that require prolonged pul-
pal anesthesia as well as treatments where restricted blood flow 
and prolonged elimination of pain through local anesthetics is 
necessary postoperatively. Although it contradicts the estab-
lished university consensus, many private practices and – ac-
cording to the manufacturer – about 96% of pediatric dentists 
use the forte compound as a rule in their daily routine, because 
the name forte implies a strong and reliable effect. In truth, 
however, the higher level of epinephrine prolongs the effective 
only insignificantly. In comparing the two epinephrine concen-
trations, which differed by a factor of 4, the study was able to 
show that even the mite compound is sufficiently effect for the 
practice of pediatric dentistry. This should make it clear to the 
practitioner that the forte compound should be used only in 
certain exceptional cases, and that an epinephrine concentra-
tion of 1:200,000 is more than enough for a standard com-
pound. In general, it is important to weigh the advantages and 
disadvantages when choosing the right anesthetic, in order to 
ensure pain-free treatment while keeping the burden borne by 
the patient to a minimum. Patients who have had experiences 
with both compounds would clearly prefer Ubistesin™ mite for 
future treatments.
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Résumé
En médecine dentaire pédiatrique, la minimisation de la dou-
leur pendant le traitement est de grande importance. Pourtant, 
l’anesthésiant local contient de l’adrénaline, qui est respon-
sable pour l’anesthésie prolongée des tissus mous. Ceci n’en-
gendre pas seulement une sensation désagréable pour les en-
fants, mais est aussi associé à un taux élevé d’effets secondaires 
(p. ex. blessures par morsure). Le but de l’étude était d’évaluer, 
si la réduction d’adrénaline dans l’anesthésiant local peut ré-
duire le temps d’anesthésie des tissus mous et ainsi le risque  
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de morsures, tout en préservant une profondeur et durée 
d’anesthésie suffisante.
Dans une étude clinique, qui a été menée dans le cadre de 
traitements routiniers d’enfants et d’adolescents, la durée 
d’anesthésie d’une solution de 4% d’Articaïne avec un taux 
 réduit d’adrénaline (Ubistesin™ mite, 1:400 000) a été compa-
rée à une solution avec un taux d’adrénaline normale (Ubiste-
sin™ forte, 1:100 000).
158 patients (mite: 75, forte: 83) ont été traités (80% avec 
anesthésie d’infiltration). Le volume d’injection moyen était 
comparable dans les deux groupes (mite: 1,2 ml, forte: 1,1 ml). 
Dans chacun des deux groupes, un patient a subi des effets se-
condaires. Dans chacun des deux groupes, une anesthésie com-
plète ou suffisante a été obtenue dans 96% des cas. Le temps  
de traitement moyen a été de 24 minutes dans le groupe mite et 
28 minutes dans le groupe forte. Concernant la durée d’anesthé-
sie des tissus mous, une différence statistiquement significative 
a été trouvée (p = 0,001, mite: 2,1 h, forte: 2,8 h).
En raison de la bonne efficacité et tolérance ainsi que de la ré-
duction de la durée d’anesthésie, la solution d’Articaïne de 4% 
avec un taux d’adrénaline réduit constitue un anesthésiant local 
adéquat pour la médecine dentaire pédiatrique.
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